Article PDF
Avoid common mistakes on your manuscript.
References
Verhoef, J., W. M. N. Hustinx, H. Frasa, and A. I. Hoepelman. 1996. Issues in the adjunct therapy of severe sepsis. J. Antimicrob. Chemother. 138: 167–182.
Nasraway, S. A. 1999. Sepsis research: we must change course. Crit. Care Med. 27: 427–430.
Baue, A. E., R. Durham, and E. Faist. 1998. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS) multiple organ failure (MOF): are we winning the battle? Shock 10: 79–89.
Opal, S. M., and R. L. Yu, Jr.1998. Antiendotoxin strategies for the prevention and treatment of septic shock: new approaches and future directions. Drugs 55: 497–508.
Cross, A. S., S. M. Opal, A. Bhattacharjee, S. T. Donta, P. M. Peduzzi, E. Furer, J. U. Que, and S. J. Cryz. 1999. Immunotherapy of sepsis: Flawed concept or faulty implementation? Vaccine 17supp; 2: S123–131.
Teplick, R. and R. Rubin. 1999. Therapy of sepsis: why have we made such little progress? Crit. Care Med. 27: 1682.
Abraham. E. 1999. Why immunomodulatory therapies have not worked in sepsis. Intens. Care Med. 25: 556–566.
Liu, M., and A. S. Slutzki. 1997. Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Intensive Care Med. 23: 718–731.
Vincent, J. L. 1997. Clinical trials in sepsis: Where do we stand? J. Crit. Care 12: 3–6.
Faist, E., and C. Kim. 1998. Therapeutic immunomodulatory approaches to the control of systemic inflammatory response syndrome and the prevention of sepsis. New Horiz. 6S:97–102.
Yao, Y. M., H. Redland, and G. Schlag. 1998. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm. Res. 47: 201–210.
Wheeler, A. P., and A. G. R. Bernard. 1999. Treating patients with severe sepsis. New Engl. J. Med. 340: 207–214.
Evans, T. W., D. Bennet, and J. F. Bion (editors). 1999. Intensive Care Medicine. Brit. Med. Bull 55: 1–302.
Ginsburg, I., and R. Kohen. 1995. Cell damage in inflammatory and infectious sites might involve a coordinated “cross-talk” among oxidants, microbial hemolysins and amphiphiles, cationic proteins phospholipases, fatty acids, proteinases and cytokines. (an overview). Free Rad. Res. 22: 489–517.
Ginsburg, I. 1999. Can we learn from the pathogenetic strategies of group A hemolytic streptococci how tissues are destroyed and organs fail in post-infectious and inflammatory sequelae? FEMS Immunol. Med. Microbiol. 25: 325–338.
Ginsburg, I. 1999. Multidrug strategies are necessary to inhibit the synergistic mechanisms causing tissue damage and organ failure in postinfectious sequelae. Inflammopharmacology 7: 207–217.
Ginsburg, I. 1994. Can hemolytic streptococci be considered “forefathers of modern phagocytes? Both cell types freely migrate in tissues and destroy host cells by a “synergistic cross-talk” among their secreted agonists. Comp. Biochem. Physiol. Pharmacol. 109C: 147–158.
Ginsburg, I. 1972. Mechanisms of cell and tissue injury induced by group A streptococci; Relation to post-streptococcal sequelae. J. Infect. Dis. 126: 294–340, 419–456.
Betschel, S. D., S. M. Borgia, N. L. Brag, D. E. Low, and J. C. S. De Asavedo. 1998. Reduced virulence of group A streptococcal Tn916 mutant that does not produce streptolysin S. Infect. Immun. 66: 1671–1679.
Shannely, T. P., D. Schriner, V. Kapur, M. Kehoe, M. J. Musser, and P. A. Ward. 1996. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect. Immun. 64: 870–877.
Lukomski, S., S. Sreevastan, C. Amberg, W. Reichardt, M. Woischnik, A. Podbielski, and M. J. Musser. 1997. Inactivation of streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotypes M3 and M49 strains. J. Clin. Invest. 99: 2574–2580.
McGowan, S. E., and J. J. Murry. 1987. Direct effect of neutrophil oxidants and elastase-induced extra cellular matrix proteolysis. Amer. J. Resp. Dis. 125: 1286–1293.
Rodell, T. C., J. C. Cherionis, and J. E. Repine. 1989. Xanthine oxidase-derived toxic oxygen metabolites contribute to lung injury from neutrophil elastase. Chest 93: 146–153.
Stevens, D. L. 1997. The toxins of group A streptococci, the flesh eating bacteria, Immunol. Invest. 26: 129–150.
Zeya, H. I., and J. K. Spitznagel. 1996. Cationic proteins of polymorphonuclear leukocyte lysosomes. II. Composition, properties and mechanisms of antibacterial action. J. Bacteriol. 91: 755–762.
Elsbach, P. 1998. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J. Leuk. Biol. 64: 14–18.
Ginsburg, I. 1987. Cationic polyelectrolytes: A new look at their possible roles as opsonins, as stimulators of the respiratory burst in leukocytes, in bacteriolysis, and as modulators of immune-complex diseases. Inflammation 11: 489–515.
Ginsburg, I. 1988. I: The biochemistry of bacteriolysis: paradoxes, facts and myths. Microbiol. Sci. 5: 137–142.
Holzheimer, R. G. 1998. The significance of endotoxin release in experimental and clinical sepsis, in surgical patients: evidence for antibiotic-induced endotoxin release? Infection 26: 77–84.
Periti, A., and A. Mazzeti. 1998. Antibiotic-induced release of bacterial cell-wall components in the pathogenesis of sepsis and septic shock: a review. J. Chemother. 10: 427–448. Ginsburg 6
Siedrazkim, K., and A. Tomasz, T. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a high vancomycin-resistant mutant Staphylococcus aureus. J. Bacteriol. 178: 2557–2566.
Kishi, K., K. Hirai, and K. Hiramtsu. 1999. Clindamycin suppresses endotoxin release by ceftazimine-treated Escherichia coli O55: B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob. Agents Chemother. 43: 616–622.
Shapira, L., W. A. Soskolne, and Y. Huri. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine production. Infect. Immun. 64: 825–828.
Le Roy, D., F. Di Padova, R. Tees, S. Lengacher, R. Landmann, M. P. Glauser, and T. Calandra. 1999. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either binding of LPS to LBP or the presentation of LPS/LBP complex to CD14. J. Immunol. 162: 7454–4760.
Lamping, N., R. Dettmer, N. W. J. Schroder, D. Pfeil, W.Y Mattaschek, R. Burger, and R. R. Schumann. 1998. LPS-binding protein protect mice from sepstic shock caused by LPS or Gram-negative bacteria. J. Clin. Invest. 101: 2065–2071.
Parson, P. E. (editorial). 1998. Interleukin-10: The ambiguity in sepsis continues. Crit. Care Med. 26: 818–819.
Steinhauser, M. L., C. M. Hogaboam, N. W. Lukacs, R. W. Strieter, and S. L. Kunkel. 1999. Multiple role of IL-12 in a model of acute septic peritonitis. J. Immunol. 162: 5437–5443.
Baggiolini, M. and B. Moser. 1997. Blocking chemokine receptors. J. Exp. Med. 186: 1189–1191.
Stevens, D. L. 1998. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin. Infect. Dis. 26: 639–641.
Weiss, M., L. L. Moldawer, and E. M. Schneider. 1999. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 93: 425–439.
Editorial. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care. Med. 25: 1095–1100.
Servansky, J. E., G. Shaked, A. Novogrodsky, Levitzki, Gazit, A. Hoffman, R. J. Elin, Z. M. Quezado, B. D. Freeman, P. Q. Eichacker, R. L. Danner, S. M. Bankds, J. Bacher, M. L. Thomas, 3rd, and C. Natanson. 1997. Tyrfostin AG556 improves survival and reduces multiorgan failure in canine Eschericia coli peritonitis. J. Clin. Invest. 99: 1966–1973.
Gallily, R., A. Yamin, Y. Waksmann, H. Ovadia, J. Wiedenfeld, A. Baer-Joseph, A. Biegon, R. Mechoulam, and E. Shoahami. XXXX. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by a non psychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283: 918–924.
Lehmann, C., K. Egerer, A. Georgiev, M. Weber, and T. Grune. 1999. Inhibition of tumor necrosis factor-release in rats experimental endotoxemia by treatment with the 21-aminosteroid U-74389G. Crit. Care Med.27: 1164–1167.
Ginsburg, I., M. Sadovnic, S. Sallon, I. Milo-Goldzweig, R. Mechoulam, A. Breuerer, D. F. Gibbs, J. Varani, S. Roberts, E. Cleator, and N. Singh. 1999. PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammapharmacology 7: 47–62.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ginsburg, I. HYPOTHESIS: Is a Failure to Prevent Bacteriolysis and the Synergy Among Microbial and Host-Derived Pro-Inflammatory Agonists the Main Contributory Factors to the Pathogenesis of Post-Infectious Sequelae?. Inflammation 25, 1–6 (2001). https://doi.org/10.1023/A:1007024809661
Issue Date:
DOI: https://doi.org/10.1023/A:1007024809661